8-K: Horizon Space II Extends Merger Deadline, Faces High Redemptions

Horizon Space Acquisition II Corp. secured a one-month extension to complete its business combination with SL Bio Ltd. but faces substantial public share redemptions.

Summary

• Horizon Space Acquisition II Corp. (HSPT) extended its deadline to complete an initial business combination by one month, from February 18, 2026, to March 18, 2026.
• The extension was facilitated by a $50,000 deposit into the Trust Account by Mr. William Wang, CEO of SL BIO Ltd., the target company.
• HSPT issued an unsecured promissory note of $50,000 to Mr. William Wang for this payment, bearing no interest and convertible into private units at $10.00 per unit.
• Shareholders approved the business combination proposals, amended M&A proposal, and sole director appointment proposal at an extraordinary general meeting on February 12, 2026.
• Shareholders also approved the MAA Amendment Proposal and Trust Amendment Proposal at another meeting on February 13, 2026.
• A significant number of public shares were rendered for redemption: 2,012,378 shares related to the business combination and an additional 4,709,337 shares related to the extension, totaling 6,721,715 shares.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing negatively due to the significant shareholder redemptions and the need for an extension, which collectively signal challenges in the business combination process and potential capital erosion.

Positives

• Shareholders approved the business combination proposals, indicating a path forward for the merger.
• The company secured a one-month extension to complete its business combination, preventing immediate liquidation.
• Shareholders approved amendments to the memorandum and articles of association and the trust agreement, providing flexibility for the extension.

Negatives

• A substantial number of public shares, 6,721,715 in total (2,012,378 for business combination + 4,709,337 for extension), were rendered for redemption, indicating significant shareholder dissent or lack of confidence.
• The company required an extension to complete its business combination, suggesting challenges in closing the deal by the original deadline.
• The extension payment was made by the CEO of the target company, Mr. William Wang, rather than the SPAC sponsor, which could indicate limited sponsor commitment or financial strain.

Risks

• Failure to consummate the business combination with SL Bio Ltd. by the extended deadline of March 18, 2026, could lead to liquidation.
• High redemption rates could significantly reduce the capital available for the combined company, impacting its future operations and valuation.
• Potential for further redemptions if additional extensions are needed or if the market reacts negatively to the current redemptions.
• Events of default on the promissory note, including failure to pay principal, bankruptcy, breach of obligations, or cross-defaults, could lead to acceleration of the note.
• The company's reliance on the sponsor and/or its designee (Mr. William Wang) for future extension payments.

Future Outlook

The company has secured a one-month extension to complete its business combination with SL Bio Ltd. and has the option for up to eleven additional one-month extensions until February 18, 2027, subject to further Extension Fees. The company is working to execute the Extension Redemption and will redeem Business Combination Redemption shares upon consummation of the business combination.

Management Comments

• "The Company currently has until February 18, 2026 to complete its initial business combination. However, the Company may extend the period of time to consummate a business combination up to twelve times, each by an additional one-month extension, up to February 18, 2027."
• "On or about February 18, 2026, an aggregate of $50,000 of the Extension Fee was deposited into the Trust Account for the Companys public shareholders (the Extension Payment) by Mr. William Wang (the Payee), which enables the Company to extend the period of time it has to consummate its initial business combination by one month from February 18, 2026 to March18, 2026 (the Extension)."

Industry Context

StockSavvy.ai notes that the SPAC market has seen increased redemptions and challenges in completing business combinations, particularly for smaller SPACs or those nearing their deadlines. The high redemption rate for Horizon Space Acquisition II Corp. is consistent with this trend, reflecting investor skepticism towards certain de-SPAC transactions and a preference for liquidity. The need for an extension, funded by the target company's CEO, further highlights the difficulties in securing sufficient capital and investor support in the current environment.

Comparison to Industry Standards

• The redemption rate of 6,721,715 shares out of an unspecified initial public float is significantly high, often exceeding the average redemption rates seen in the SPAC market, which have historically ranged from 50-80% in recent years for less successful deals. For example, some SPACs like Gores Holdings VIII (GIIX) or Digital World Acquisition Corp. (DWAC) have faced high redemptions, but 6.7 million shares is a substantial number, potentially leaving a much smaller trust.
• The extension fee of $50,000 or $0.033 per public share is a common mechanism for SPACs to buy more time, but the funding coming from the target company's CEO (Mr. William Wang of SL Bio Ltd.) rather than the SPAC sponsor (Horizon Space Acquisition II Sponsor Corp.) is less common and could signal a lack of confidence or financial capacity from the original sponsor.
• The conversion of the promissory note into private units at $10.00 per unit is standard for SPAC private placements (PIPEs) or sponsor-related financing, aligning with the typical IPO price of SPAC units.

Corporate Governance

Related Party Transactions

• Mr. William Wang, CEO of SL BIO Ltd. (the target company), provided a $50,000 Extension Payment to the Company and received an unsecured promissory note in return. This is a transaction between the SPAC and an executive of its merger target.

Stakeholder Impact

• Shareholders: Those who redeemed their shares will receive their pro-rata portion of the trust account. Remaining shareholders face increased uncertainty due to the high redemption rate and the need for an extension, potentially leading to a smaller post-merger entity.
• SL BIO Ltd. (Target Company): The CEO's direct financial contribution (Extension Payment) indicates commitment to the merger but also highlights the SPAC's challenges, which could impact the combined entity's initial capital.
• Sponsor (Horizon Space Acquisition II Sponsor Corp.): The sponsor did not fund this extension, which could imply reduced financial commitment or capacity, shifting the burden to the target's CEO.

Next Steps

• Complete the initial business combination with SL Bio Ltd. by the extended deadline of March 18, 2026.
• Execute the Extension Redemption with the trust agent.
• Redeem public shares rendered for the Business Combination Redemption upon and following the consummation of the Business Combination.
• Potentially utilize up to eleven additional one-month extensions, each requiring an Extension Fee deposit.

Key Dates

Recommendation

The extremely high redemption rate, coupled with the need for an extension funded by the target company's CEO, signals significant investor apprehension and potential capital shortfalls for the combined entity. This situation creates substantial uncertainty and downside risk for remaining shareholders, making a "sell" recommendation prudent for investors seeking to avoid further value erosion.

Keywords

SPAC, Business Combination, Merger, Redemption, Extension, Promissory Note, SL Bio Ltd., Horizon Space Acquisition II Corp., HSPT, De-SPAC, Shareholder Vote